PHARMAJET INC.
GOLDEN, CO

Mr. Jordan has a Bachelor of Science degree in Mechanical Engineering from the United States Military Academy at West Point and a MBA from the University of Maryland. Jeff has more than 20 years of experience in corporate finance. In his previous role, he directed the global finance functions for the Laboratory Products Group of Thermo Fisher Scientific, supporting $1.9B in annual revenue and 10,000 employees. Jeff has worked in several industries including life science tools, telecommunications and industrial chemicals. He has extensive experience in strategic planning, forecasting, significant capital investments, acquisitions and integration activities. Vice Chairman and Chief Business Development Officer Ms. Callender-Potters has a Bachelor of Arts degree in International Management from Claremont McKenna College and an MBA from Wharton, the University of Pennsylvania. One of the co-founders of the company, Heather has 23 years of Private Equity fund management and international investment (BCEE; Enterprise Investors) across multiple jurisdictions, and has managed individual investments and financial investor consortiums, ranging from $1 million to an excess of $100 million. She has also held board positions with several companies across a variety of industries ranging from auto-parts, to systems integration, publishing, and light-manufacturing. As a physician/scientist Paul has researched and published extensively on the role antibiotic resistance mechanisms play in infectious disease, particularly with Haemophilus influenza. As a pediatrician, his contributions include vaccine safety, efficacy, effectiveness and immunogenicity studies in influenza, hepatitis B, Haemophilus type B, pneumococcal conjugate and other vaccines. While serving as VP Clinical Research at Aviron, then VP and Group Leader, Clinical Development at MedImmune, Paul was integral to the clinical and commercial development of the intranasal influenza vaccine FluMist. He currently serves as Chief Medical Officer and Executive VP of LigoCyte Pharmaceuticals, a clinical-stage biologic drug development company focused on respiratory and gastrointestinal indications utilizing a proprietary virus-like particle (VLP) technology. Vice Chairman and Chief Business Development Officer One of the co-founders and active in the management of PharmaJet, Heather has 23 years of private equity fund management and international investment experience across multiple jurisdictions, managing individual investments and financial investment consortiums. She has a BA in International Management from Claremont McKenna College and an MBA from Wharton, the University of Pennsylvania. Mr. Buckley has a background as a commercial real estate developer, with investments spanning the US and Canada. He is an active angel investor in high- tech and bio-tech companies, which includes medical devices and tools that aid in drug delivery and diagnostic activities. Spike is an active board participant in the Colorado Veterinary Medical Foundation, Alameda Corridor Business Improvement District and CryptoMill Technologies. He holds a BA in Economics from the University of Colorado. Mr. Marcaccio is Managing Director and Chief Financial Officer in the Office of the Chairman of Katz Group, where he focuses on financing, capital deployment and financial oversight of the various group businesses, and supports new business ventures. Prior to its sale to McKesson Corporation, he also had direct oversight of the Group’s Rexall Health business. Previously, he was a Partner in the Corporate Finance practice at PricewaterhouseCoopers. Paul has over 30 years of experience advising, building and leading businesses through strategic growth and development. He holds a BA in Economics from the University of Western Ontario and an MBA from McMaster University. IPI publishes PharmaJet article The spring-powered PharmaJet Needle-free Injectors use a narrow stream of fluid that goes through the skin, without a needle, in about 1/10 Sign up for PharmaJet updates